RT Journal Article
T1 Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19.
A1 Jimenez-Cortegana, Carlos
A1 Sanchez-Jimenez, Flora
A1 Perez-Perez, Antonio
A1 Alvarez, Nerissa
A1 Sousa, Alberto
A1 Canton-Bulnes, Luisa
A1 Vilariño-Garcia, Teresa
A1 Fuentes, Sandra
A1 Martin, Salomon
A1 Jimenez, Marta
A1 Leon-Justel, Antonio
A1 de la Cruz-Merino, Luis
A1 Garnacho-Montero, Jose
A1 Sanchez-Margalet, Victor
K1 COVID-19
K1 ICU
K1 MDSCs
K1 OX40
K1 PD-1
K1 SARS-CoV2
K1 Tregs
AB Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a disease (coronavirus disease 2019, COVID-19) that may develop into a systemic disease with immunosuppression and death in its severe form. Myeloid-derived suppressive cells (MDSCs) are inhibitory cells that contribute to immunosuppression in patients with cancer and infection. Increased levels of MDSCs have been found in COVID-19 patients, although their role in the pathogenesis of severe COVID-19 has not been clarified. For this reason, we raised the question whether MDSCs could be useful in the follow-up of patients with severe COVID-19 in the intensive care unit (ICU). Thus, we monitored the immunological cells, including MDSCs, in 80 patients admitted into the ICU. After 1, 2, and 3 weeks, we examined for a possible association with mortality (40 patients). Although the basal levels of circulating MDSCs did not discriminate between the two groups of patients, the last measurement before the endpoint (death or ICU discharge) showed that patients discharged alive from the ICU had lower levels of granulocytic MDSCs (G-MDSCs), higher levels of activated lymphocytes, and lower levels of exhausted lymphocytes compared with patients who had a bad evolution (death). In conclusion, a steady increase of G-MDSCs during the follow-up of patients with severe COVID-19 was found in those who eventually died.
YR 2022
FD 2022-01-28
LK http://hdl.handle.net/10668/20577
UL http://hdl.handle.net/10668/20577
LA en
NO Jiménez-Cortegana C, Sánchez-Jiménez F, Pérez-Pérez A, Álvarez N, Sousa A, Cantón-Bulnes L, et al. Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19. Front Immunol. 2022 Jan 28;12:801410
DS RISalud
RD Jul 29, 2025